Oblimersen and Gemtuzumab Ozogamicin in Treating Older Patients With Relapsed Acute Myeloid Leukemia
Status:
Completed
Trial end date:
2006-05-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Monoclonal antibodies such as gemtuzumab ozogamicin can locate tumor cells and
either kill them or deliver tumor-killing substances to them without harming normal cells.
Oblimersen may help gemtuzumab ozogamicin kill more cancer cells by making cancer cells more
sensitive to the drug.
PURPOSE: Phase II trial to study the effectiveness of combining oblimersen and gemtuzumab
ozogamicin in treating older patients who have relapsed acute myeloid leukemia.